Medtech company wins award for 'game-changing innovation'

BellaSeno, an ISO 13485-certified medtech company which develops absorbable scaffolds using additive manufacturing technologies, has received a Bronze Edison Award for its Senella implant technology.

The award was for the subcategory Medical Implants within the Medical/Dental category and was chosen by a panel of over 3,000 leading business executives from all around the world.

Senella is a patented porous scaffold made of absorbable PolyCaproLactone (PCL).  This polymer is often used as an additive for resins to improve their processing characteristics and their end use properties e.g. it can be added as a plasticiser to PolyVinyl Chloride (PVC). The technology contains highly-specialised topological and design features which act as recipients for injected fat tissue isolated with a standard liposuction procedure.

The implant is designed to be absorbed over two years and to provide a stable platform for the injected fat tissue to mature, adapt to its environment and stabilise. The end result is a natural breast tissue – without remnants of foreign material. Therefore, Senella has the potential to alleviate complications found in current breast reconstruction and augmentation approaches.

Frank Bonafilia, executive director of the Edison Awards commented: “After a thorough review, the Edison Awards judges recognise Senella as a game-changing innovation standing out among the best new products and services launched in their category.”

Dr. Mohit P. Chhaya, co-founder and chief technology officer of BellaSeno said: “Senella is a result of more than ten years of research and development efforts.

"I would like to thank the entire BellaSeno team for their untiring efforts and their collaborative spirit that made this success possible.”

Sara Lucarotti, head of design of BellaSeno added: "We are proud to have received a Bronze Edison Award for our proprietary Senella technology. Our novel breast implants are designed to significantly limit the risk of potential side-effects common in breast reconstruction. Ultimately, our goal is to provide breast reconstruction patients with fully natural breasts and a high quality of life after surgery."